PA
STOK icon

Parallel Advisors’s Stoke Therapeutics STOK Stock Holding History

Parallel Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$423 Hold
13
– – ﹤0.01% 3697
2025
Q4 		$413 Buy
+13
New +$391 ﹤0.01% 3431
2025
Q2 		– Sell
-24
Closed -$160 – 3692
2025
Q1 		$160 Buy
+24
New +$224 ﹤0.01% 3411
2023
Q3 		– Sell
-57
Closed -$606 – 3482
2023
Q2 		$606 Hold
57
– – ﹤0.01% 3061
2023
Q1 		$475 Hold
57
– – ﹤0.01% 3134
2022
Q4 		$526 Buy
+57
New +$593 ﹤0.01% 3025

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Parallel Advisors's STOK Position: Q1 2026 in Review

Parallel Advisors held its Stoke Therapeutics (STOK) position steady in Q1 2026 at 13 shares worth $423. The position accounts for ﹤0.01% of the portfolio, ranked #3697.

Parallel Advisors first reported a position in STOK in Q4 2022 and has held it in 6 quarters since. The position peaked at $606 in Q2 2023. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Parallel Advisors held 13 shares of Stoke Therapeutics worth $423 as of Q1 2026.
  • Parallel Advisors left its Stoke Therapeutics share count unchanged in Q1 2026.
  • Stoke Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3697 holding.
  • Parallel Advisors first reported a position in Stoke Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • Parallel Advisors's Stoke Therapeutics position peaked at $606 in Q2 2023.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.